Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

OBJECTIVES: To evaluate the cost-effectiveness of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in basal–bolus regimens for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk based on the DEVOTE CV outcomes trial. METHODS: A microsimulation model,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Appl Health Econ Health Policy
Autors principals: Pollock, Richard F., Valentine, William J., Marso, Steven P., Andersen, Andreas, Gundgaard, Jens, Hallén, Nino, Tutkunkardas, Deniz, Magnuson, Elizabeth A., Buse, John B.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2019
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6748892/
https://ncbi.nlm.nih.gov/pubmed/31264138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40258-019-00494-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars